The fibroblast growth factor (FGF) family is a ubiquitous intrinsic mediator of development and adult homeostasis whose dysfunction potentially underlies tissue-specific pathologies. The FGF signal transduction complex signals changes in the local environment through assembly of its three participants into an oligomeric complex that undergoes trans-activation. The FGF polypeptides have grown to seventeen genetically distinct homologues. The transmembrane tyrosine kinase receptor (FGFR) consists of the products of at least 16 single site splice variations in four genes, which form combinatorial variants in the extracellular, intracellular juxtamembrane and C-terminal intracellular domains. The complex is an integral part of the peri-cellular matrix through its heparan sulfate subunit. Using combined immunochemical, biochemical, molecular and cellular approaches and collaborations for direct structural analysis, this continuation project will apply a modular approach to attempt to directly determine structure of the FGFR ectodomain by x-ray crystallography. It will determine whether isolated heparin-Ig module II from the four FGFR exhibits preference for FGF ligands and will determine the role of individual residues and subdomains in the 16-residue homeo-interaction sequence of FGFR in direct interaction, signaling by activation of Fire-Luc, acquisition of mitogenesis in epithelial cells and stoichiometry of the FGFR complex. The Fire-Luc system has been validated as a useful transcriptional reporter for FGFR activity. The project will determine the preference and interaction characteristics of defined oligosaccharides of heparin with FGF-1, FGF-7, FGF-10 and isolated Ig module II from FGFR1-4, and use the optimal oligosaccharides for co-crystallization with the respective molecules. The novel Fire-Luc transcriptional reporter for FGFR1 kinase activity and the acquisition of an FGFR1 mitogenic response in epithelial cells to characterize the role and specificity of the intracellular juxtamembrane sequence, the kinase core, the variant C-terminus and three specific phosphotyrosines and their combinations will be employed. The project will try to complete the resolution of the FGF-7 structure without and with bound heparin mimics and heparin oligosaccharides, as well as FGF-10 and a structural/functional chimeric FGF-7/FGF-1 construct. The work will perform and refine site-directed mutagenesis studies on FGF-7, FGF-10 and chimeric derivatives. These results are essential to understand the molecular basis of the multiple functions of FGF action in health and disease and the rational design of both ligand and receptor antagonists.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
7R01DK040739-12
Application #
6312114
Study Section
Cellular Biology and Physiology Subcommittee 1 (CBY)
Program Officer
Sato, Sheryl M
Project Start
1989-02-01
Project End
2003-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
12
Fiscal Year
2000
Total Cost
$248,412
Indirect Cost
Name
Texas A&M University
Department
Type
Schools of Medicine
DUNS #
City
College Station
State
TX
Country
United States
Zip Code
77845
Jin, Chengliu; Wang, Fen; Wu, Xiaochong et al. (2004) Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors. Cancer Res 64:4555-62
Luo, Yongde; Cho, Hyun-Hee; McKeehan, Wallace L (2003) Biospecific extraction and neutralization of anticoagulant heparin with fibroblast growth factors (FGF). J Pharm Sci 92:2117-27
Wang, Fen; McKeehan, Kerstin; Yu, Chundong et al. (2002) Fibroblast growth factor receptor 1 phosphotyrosine 766: molecular target for prevention of progression of prostate tumors to malignancy. Cancer Res 62:1898-903
Wu, X; Kan, M; Wang, F et al. (2001) A rare premalignant prostate tumor epithelial cell syndecan-1 forms a fibroblast growth factor-binding complex with progression-promoting ectopic fibroblast growth factor receptor 1. Cancer Res 61:5295-302
Murakami, S; Kan, M; McKeehan, W L et al. (2000) Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A 97:1113-8
McKeehan, W L; Wu, X; Kan, M (1999) Requirement for anticoagulant heparan sulfate in the fibroblast growth factor receptor complex. J Biol Chem 274:21511-4
Lu, W; Luo, Y; Kan, M et al. (1999) Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 274:12827-34
Kan, M; Wu, X; Wang, F et al. (1999) Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem 274:15947-52
Luo, Y; Lu, W; Mohamedali, K A et al. (1998) The glycine box: a determinant of specificity for fibroblast growth factor. Biochemistry 37:16506-15
Zhou, F Y; Kan, M; Owens, R T et al. (1997) Heparin-dependent fibroblast growth factor activities: effects of defined heparin oligosaccharides. Eur J Cell Biol 73:71-80

Showing the most recent 10 out of 21 publications